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Background: Norwegian hospitals have operated within capacity during the 
COVID- 19 pandemic. We present patient and management characteristics, and 
outcomes for the entire cohort of adult (>18 years) COVID- 19 patients admitted to 
Norwegian intensive care units (ICU) from 10 March to 19 June 2020.
Methods: Data were collected from The Norwegian intensive care and pandemic 
registry (NIPaR). Demographics, co- morbidities, management characteristics and 
outcomes are described. ICU length of stay (LOS) was analysed with linear regres-
sion, and associations between risk factors and mortality were quantified using Cox 
regression.
Results: In total, 217 patients were included. The male to female ratio was 3:1 and 
the median age was 63 years. A majority (70%) had one or more co- morbidities, most 
frequently cardiovascular disease (39%), chronic lung disease (22%), diabetes mellitus 
(20%), and obesity (17%). Most patients were admitted for acute hypoxaemic respira-
tory failure (AHRF) (91%) and invasive mechanical ventilation (MV) was used in 86%, 
prone ventilation in 38% and 25% of patients received a tracheostomy. Vasoactive 
drugs were used in 79% and renal replacement therapy in 15%. Median ICU LOS and 
time of MV was 14.0 and 12.0 days. At end of follow- up 45 patients (21%) were dead. 
Age, co- morbidities and severity of illness at admission were predictive of death. 
Severity of AHRF and male gender were associated with LOS.
Conclusions: In this national cohort of COVID- 19 patients, mortality was low and at-
tributable to known risk factors. Importantly, prolonged length- of- stay must be taken 
into account when planning for resource allocation for any next surge.
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1  | INTRODUC TION
Critically ill patients infected with the SARS- CoV- 2 virus (COVID- 19 
patients) typically present with acute hypoxaemic respiratory fail-
ure (AHRF) due to viral pneumonia. This may progress to acute res-
piratory distress syndrome (ARDS), a common but underrecognized 
cause of admission to the intensive care unit (ICU) that is associated 
with high mortality rates and significant morbidity in survivors.1,2 
Such patients are managed in the ICU with generic measures, in-
cluding invasive mechanical ventilation (MV), in accordance with 
evidence- based clinical practice guidelines.3- 6
Mortality rates in ARDS of mixed aetiologies depend on patients’ 
co- morbidities and age, severity of hypoxaemia and co- existing 
organ failures.7 In the “large observational study to understand 
the global impact of severe acute respiratory failure” (LUNG SAFE), 
overall mortality for patients with ARDS was 40%.8 The findings 
have pointed to a need for improved recognition of ARDS at an early 
stage, strict adherence to evidence- based strategies and attention 
to modifiable risk factors.7 Moreover, there is a geo- economic gra-
dient in mortality from high- income regions to low- and middle- 
income regions.9
Early reports of the management of critically ill COVID- 19 pa-
tients were described in the context of health care systems that 
were initially overwhelmed by large numbers of patients, often 
exceeding the surge capacity many hospitals had planned for in 
the event of a pandemic.10,11 Reported mortality rates for MV pa-
tients with COVID- 19 have been high, ranging from 61.5% (China),12 
53.4% (Italy),13 50% (Seattle),14 49.4% (UK),15 43.6% (New York).16 
This contrasts with outcome data for critically ill patients with non- 
COVID- 19 viral pneumonia, eg, influenza, where mortality has been 
found to be considerably lower.15
More recently, data have emerged from healthcare systems 
where hospital capacity has not been strained, allowing intensive care 
units to provide care in accordance with established clinical practice. 
Although case- mix may differ, evidence is emerging that mortality in 
the critically ill may be lower under such circumstances.17- 20
The first Norwegian to test positive for SARS- CoV- 2 was identi-
fied 21 February 2020. This patient was probably infected in China.21 
Following this, a surge of patients (mostly vacationers returning from 
Northern Italy and Austria) initiated track- and- trace activities and 
use of quarantine. When routes of transmission could no longer be 
identified, Norwegian authorities initiated a society- wide lockdown 
beginning 12 March, including border closures, travel restrictions for 
health care personnel, closure of universities, schools and kindergar-
tens. The public was barred from participation in nonessential ac-
tivities (meetings, restaurants and pubs, sports) and the authorities 
encouraged working from home for whomever this was an option.22 
After a slow lifting of restrictions beginning 27 April, only minor local 
outbreaks followed until a limited “second wave” occurred in the au-
tumn months of 2020.
Norwegian authorities organised several webinars early March, 
addressing the management and care for COVID- 19 patients, urging 
preparedness in all hospitals for a surge of patients with AHRF, and 
stressing the importance of evidence based supportive care, includ-
ing MV.3 Hospitals were also warned that in a scenario of strained 
ICU- capacity, most units must be prepared to manage such patients 
without referral to university clinics. Use of corticosteroids and ex-
perimental therapies, including anti- virals, outside of clinical trials 
was actively discouraged.
In this paper we describe characteristics and management of 
the first wave of critically ill COVID- 19 patients admitted to ICUs in 
Norway (March 10- June 19) and investigate factors associated with 
survival and length- of- stay in the ICU.
2  | METHODS
2.1 | Participants
We included all adult patients (>18 years) who were admitted to a 
Norwegian ICU with a diagnosis of COVID- 19, between 10 March 
2020 and 19 June 2020.
2.2 | Ethics
This study was approved by the South- East Norway Regional 
Committee for Medical and Health Research Ethics (reference no. 
135310), with a waiver for informed consent. This study was regis-
tered at ClinicalTrials.gov (NCT04601090).
2.3 | Organisation and data collection
The present study is a collaboration between Oslo University 
Hospital and the Norwegian Intensive Care and Pandemic Registry 
(NIPaR), a national registry established in 1998. Since 2011, NIPaR 
collects individual data from all ICU- admissions in Norway, re-
corded securely via a web- based platform. The ordinary dataset 
includes patient demographics, acute physiology scores at admis-
sion, nursing workload, select treatment measures, complications 
and mortality. Reports with aggregate data are regularly published 
online and are freely available, as are detailed descriptions of 
variables.23,24 From the start of the present pandemic, select co- 
morbidities and entries for the type and duration of ventilatory 
support and extracorporeal membrane oxygenation (ECMO) were 
Editorial Comment
This report present a comprehensive and complete na-
tional dataset that includes all COVID- 19 patients admit-
ted to Norwegian ICUs. It describes a cross- section of both 
patients and their management in Norwegian ICUs during 
the first phase of the pandemic.
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added. By late March 2020, Norwegian authorities requested that 
the registry be further expanded to collect national data from any 
patient admitted to hospital with a positive test for SARS- CoV- 2. 
This dataset for pandemic patients includes demographics, co- 
morbidities, findings at the day of admission, antibiotics and clas-
sification of organ system dysfunction. Use of experimental drugs 
was not recorded. Detailed information regarding the variables is 
freely available online.23,25 Data from the intensive care registry 
and the pandemic dataset was used to conduct this observational 
study of short- term outcomes of COVID- 19 patients admitted to 
Norwegian ICUs (this paper).
We have also collected follow- up data corresponding to a ‘core 
outcome measurement set’ developed through an international 
Delphi- process for ICU patients with acute respiratory failure.26,27 
This will address the physical, psychological and cognitive health re-
lated challenges occurring after ICU treatment commonly described 
as “post- ICU syndrome”.28,29
2.4 | Definitions
The primary cause for ICU- admission and the identification of ARDS 
in individual patients, were provided at clinicians’ discretion. We 
did not have access to chest x- ray data or ventilator settings ex-
cept for the ratio of arterial oxygen partial pressure to fractional 
inspired oxygen (pf- ratio) at the day of admission. For statistical 
analysis, we therefore classified patients according to the severity 
of acute hypoxaemic respiratory failure (AHRF) defined as either ‘no 
invasive ventilation’ or, in invasively ventilated patients as ‘mild’ (pf- 
ratio > 26.6 kPa), ‘moderate’ (pf- ratio > 13.3 kPa and ≤26.6 kPa) or 
‘severe’ (pf- ratio ≤ 13.3 kPa) depending on the pf- ratio, on the first 
day of admission.
2.5 | Statistical analyses
Data are presented as descriptive statistics and we used time- to- 
event techniques to analyze survival after ICU admission. Categorical 
variables are reported as frequencies (percentages) and continuous 
variables as medians (with interquartile ranges [IQRs]) or means 
(with SDs).
Vital status was determined for all patients from the National 
Population Registry as of June 27, 2020. Kaplan- Meier survival es-
timates and Cox proportional hazards models were used to assess 
association between patient characteristics and mortality. ICU mor-
tality rates were calculated by patient status at ICU discharge.
Days from ICU admission to death (event) or June 27, 2020 (cen-
soring), constituted the time of analysis. At the time of censoring, all 
patients in this dataset were either discharged from, or dead in the 
ICU. For patients readmitted to the ICU after discharge, the first ICU 
admission was considered in the analysis. We did not include patient 
management data in multivariable analysis due to the risk of time- 
dependent bias (immortal time bias) and lack of statistical power to 
model this with sufficient precision. ICU LOS was log transformed 
and analysed with multiple linear regression using demographic 
data, co- morbidities and severity of illness measures as indepen-
dent variables. All tests were two- sided and P- values < 0.05 were 
considered statistically significant. As this study was exploratory, no 
correction for multiple testing was done.




Patients’ baseline characteristics are presented in Table 1 (see 
also Appendix Table A1). Critically ill patients were predominantly 
male, with a median age of 63 years, and most with one or more co- 
morbidities involving vital organ systems; cardiovascular disorders, 
lung- and kidney disease, as well as diabetes and obesity. However, 
in almost one- third of patients no co- morbid disease was registered 
by clinicians and one- fifth of patients were less than fifty years old. 
The cause of ICU- admission (as per clinicians’ assessment) was in 
most cases acute respiratory failure (91.2%) (Table 1). On the first 
day of admission 161 patients (74.2%) required MV, with predomi-
nantly moderate or severe hypoxemic respiratory failure according 
to the ratio of arterial oxygen partial pressure to fractional inspired 
oxygen (pf- ratio) (Table 1). Thirty- four patients (15.7%) did not re-
quire MV during the first day in the ICU. We could not account for 
the ventilation needs on the day of admission for 22 patients. Forty- 
three patients (19.8%) had elevated s- urea and systolic blood pres-
sure was lower than 100 mm Hg in 112 patients (51.6%) on the first 
day of admission. Respiratory failure was categorized as ARDS by 
clinicians in 91 patients (41.9%). Median SAPS II- score was 33.
A majority of patients were admitted between 10 March and 1 
May (Figure 1) and 159 (73.3%) were admitted to hospitals in South- 
East Norway (capital- region) (Appendix Table A2).
3.2 | Management
Median LOS in the ICU was 14.0 days (range 0.7- 69.0 days) (Table 2). 
One- hundred and eighty- seven patients (86.2%) were managed with 
MV for a median of 12.0 days and 84 patients (38.7%) were man-
aged with non- invasive ventilation for a median of 0.7 days. Eighty- 
three patients (38.2%) were managed in the prone position for a 
median of 5 days. We have no record of prone positioning in non-
 MV patients. Vaso- active agents were used in a majority of patients. 
Thirty- two patients (14.7%) received renal replacement therapy 
(RRT). Tracheotomy was performed in 54 patients (24.9%). Median 
LOS and time on MV were 31.5 and 26.3 days, respectively, for tra-
cheotomized patients (Appendix Table A4). Other adjuncts (ECMO, 
nitric oxide) were used sparingly and additional data on ventilator 
management was not collected.
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3.3 | Outcomes
Patients were followed for a median of 89 days after ICU- 
admission. In total, 177 patients (81.6%) were alive at discharge 
from the ICU and forty patients (18.4%) died in the ICU. At the 
end of follow- up forty- five patients (20.7%) were dead with a me-
dian ICU LOS of 12.1 days and no patient remained in the ICU 
(Table 3).
Mortality rates varied depending on patient demographics and 
co- morbidities, management characteristics and severity of illness 
at admission (Table 3 and Figure 2). There were marked differences 
in mortality in elderly vs younger patients and mortality was higher 
in patients with co- morbidities. We performed several multivariable 
analyses to assess the impact of individual patient and disease char-
acteristics on outcomes (Appendix Table A3). In a simplified model, we 
included age, the most frequently reported co- morbidities as well as 
co- morbidities that were significantly associated with mortality at uni-
variate analysis. Age ≥ 65 years (hazard ratio [HR] 3.01), diabetes (HR 
2.41) and chronic kidney disease (HR 2.89) were strongly associated 
with higher mortality (Table 4A).
Severity of illness at admission and management characteristics 
were also associated with different mortality rates; Patients pre-
senting with severe acute respiratory failure, signs of kidney injury 
or circulatory failure, all had higher mortality (Table 3). In multivari-
able analysis, signs of kidney injury at admission (elevated s- urea) 
were independently and statistically significantly associated with 
death (HR 3.89) (Table 4b). The median SAPS II score was 33 and 





Male (n, %) 162 74.7
Female (n, %) 55 25.3
Age (median, IQR) 63.0 54.2, 72.2
25- 49 (n, %) 36 16.6
50- 64 (n, %) 86 39.6
65- 79 (n, %) 80 36.9
≥80 (n, %) 15 6.9
Co- morbidities and risk factors
Any risk factor / co- morbidity (n, %) 152 70.0
Number of co- morbidities
0 (n, %) 65 30.0
1 (n, %) 74 34.1
2 (n, %) 46 21.2
3 (n, %) 25 11.5
>3 (n, %) 7 3.2
Cardiovascular disease (incl. 
Hypertension) (n, %)
84 38.7
Diabetes mellitus (n, %) 43 19.8
Obesity (BMI > 30) (n, %) 38 17.5
Asthma (n, %) 32 14.8
Chronic lung disease (n, %) 18 8.3
Chronic kidney disease (n, %) 18 8.5
Impaired immune system including 
HIV (n, %)
18 8.1
Cancer (n, %) 8 3.7
Neurologic or neuromuscular disease 
(n, %)
7 3.2
Active smoker (n, %) 4 1.8
Liver disease (n, %) 1 0.5
Pregnancy (n, %) 0 0.0
No co- morbidity/risk factor (n, %) 65 30.0
Cause for ICU admission
Respiratory (n, %) 198 91.2
Circulatory (n, %) 4 1.8
Gastroenterological (n, %) 1 0.5
Neurological (n, %) 1 0.5
Sepsis (n, %) 5 2.3
Metabolic (n, %) 1 0.5
Renal (n, %) 1 0.5
Other (n, %) 6 2.7
Illness severity at admission
Systolic blood pressure
<70 mm Hg (n, %) 13 6.0






100- 199 mm Hg (n, %) 97 44.7
≥200 mm Hg (n, %) 8 3.7
Acute hypoxaemic respiratory failureb 
Not mechanically ventilated (n, %) 34 15.7
Mild hypoxaemiaa  (n, %) 17 7.8
Moderate hypoxaemiaa  (n, %) 104 47.9
Severe hypoxaemiaa  (n, %) 40 18.4
Kidney injuryc 
S- UREA < 10 mmol/L (n, %) 173 79.7
S- UREA 10- 29.9 mmol/L (n, %) 39 18.0
S- UREA ≥ 30.00 mmol/L (n, %) 4 1.8
SAPS II- score (n = 217) (median, IQR) 33 26, 41
Clinical Frailty Scale (n = 129) 
(median, IQR)
2 2, 3
aMild = pf- ratio > 26.6 kPa (>200 mm Hg); moderate = pf- 
rato > 13.3 kPa and ≤ 26.6 kPa (>100 mm Hg and ≤ 200 mm Hg); 
severe = pf- ratio ≤ 13.3 kPa (≤100 mm Hg). 
bMissing: 22 pts. 
cMissing: 1 pt. 
TA B L E  1   (Continued)
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was a prognostic factor for death in ICU with moderate accuracy 
(area under the receiver operating characteristic (ROC) curve = 0.71, 
95% CI [0.62- 0.79]) (Appendix Figure A1L).
Mortality was higher in patients requiring organ support (me-
chanical ventilation, renal replacement therapy or vasoactive in-
fusion) at any point during their stay in the ICU (Table 3). Notably, 
patients requiring renal replacement therapy had markedly higher 
mortality (53.1%) than patients who were managed without. 
Clinicians’ identification of ARDS in these patients was of little con-
sequence for mortality but was associated with prolonged ICU LOS 
(Appendix Figure A1H, Table A5).
3.4 | Resource utilisation
Mean ICU LOS and days of MV were 17.4 and 15.2, respectively 
(Table 5). This amounts to a total of 3771.8 days in ICU and 2840.9 days 
on MV (75.3% of ICU days). In contrast, non- invasive ventilation was 
used for only 103.6 days (2.7% of ICU- days) and renal replacement 
therapy for 335 days (8.9% of ICU- days). The mean “Nine equivalents 
of nursing manpower use score” (NEMS) per patient was 602.2. (34.6 
per day in ICU). Male gender, severity of respiratory failure at admission 
and patients’ respiratory failure classified as ARDS were all statistically 
significantly associated with LOS (Figure 3 and Appendix Table A5).
4  | DISCUSSION
In Norway, early public health measures resulted in a low burden 
of disease from COVID- 19 during spring 2020.30 As a consequence, 
the number of critically ill COVID- 19 patients has been low and 
Norwegian hospitals have with few exceptions been able to re-
main operative within capacity, allowing management of critically 













Date of ICU admission
TA B L E  2   Clinical management
Median, IQR n (%)
ICU- LOS (days) 14.0 (6.9, 23.0) 217 (100)
MV (days) 12.0 (6.7, 20.4) 187 (86.2)
MV in prone position (days) 5 (2.0, 8.0) 83 (38.2)
Non- invasive ventilation 
(days)
0.7 (0.2, 1.6) 84 (38.7)
Tracheostomy
ICU LOS (days) 31.5 (24.1, 45.2) 54 (24.9)
Mechanical ventilation 
(days)
26.3 (19.8, 38.3) 54 (24.9)
ECMO (days)a  (8.7, 26.3)a  2 (0.9)
Nitric oxide 1(0.5%)
RRT (days) 9 (5.0, 15.0) 32 (14.7)
IHD (days) 6 (2.0, 7.0) 12 (5.5)
CRRT (days) 8.5 (5.0, 13.5) 28 (12.9)
Vaso- active drugs - 171 (78.8)
NEMS- score (median, IQR) 513 (227, 784) 213 (98.2)
Abbreviations: ICU LOS, intensive care length- of- stay; MV, mechanical 
ventilation; ECMO, extracorporeal membrane oxygenation; RRT, 
renal replacement therapy; IHD, intermittent haemodialysis; CRRT, 
continuous renal replacement therapy; NEMS, nine equivalents of 
nursing manpower score.
aRange. 
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ill patients to proceed according to established routines and with 
experienced staff.
In this cohort of 217 SARS CoV2 positive patients admitted to 
Norwegian ICUs between March 10- June 19, ICU mortality was 
18.4% (20.3% in MV patients). This compares favourably with 
early reports of very high mortality rates in critically ill COVID- 19 
patients,10,12,15,16 and aligns with reports from other countries and 
regions with early and effective lockdown- policies or a low disease 
burden.17- 20,31 ICU LOS was prolonged, and associated with male 
gender, severity of respiratory failure at admission and being clas-
sified as ARDS.
Case- mix is a strong determinant of mortality in critically ill 
populations. Age and sex, co- morbidities and frailty are non- 
modifiable risk factors in patients with ARDS.7 In this Norwegian 
cohort, such risk factors were roughly similar to those observed 
in other populations,13,32 with a high prevalence of cardiovascular 
disease, diabetes and obesity, but our data suffer from an absence 
of data on the severity of co- morbid conditions. The small number 
of patients in our cohort precludes detailed analysis of the impact 
of all relevant risk factors. Age, diabetes and chronic kidney dis-
ease were all independently associated with mortality. Notably, 
however, the median age of our population was 63 years, similar 
to that observed in Italy13 and intermediate of that observed in 
Denmark (68 years)33 and Iceland (64 years),34 and that found in 
Sweden (61 years),35 and the UK (60 years).32 It should be noted 
that admission to intensive care of nursing home residents is rarely 
deemed appropriate in Norway. In our cohort, the median clinical 
frailty scale36 was 2 (“well”) but was too infrequently reported to 
be included in analysis.
Severity of acute respiratory failure and other organ manifes-
tations at admission was associated with mortality and LOS in the 
ICU. The median SAPS II- score recorded was 33, ie, lower than we 
anticipated and indicating that in Norway, the individual disease 
burden (or severity of illness) of critically ill covid- 19 patients was 
relatively low. A median NEMS- score at 34.6 per day in the ICU 
also reflects a moderate number of interventions in our cohort 
but does not accurately reflect the nurse:patient ratio, which is 
never less than 1 in a Norwegian ICU. Whereas the median LOS in 
Norwegian ICUs is 2.0 days,24 median ICU LOS for the COVID- 19 
cohort was 14.0 days. Taking into consideration these patients 
were managed under strict isolation, that a median of 12.0 days 
were spent on MV and that 38.2% of patients required MV in the 
prone position for a median of 5 days, resource utilization was 
considerable.
Potentially preventable or modifiable risk factors in severe 
respiratory failure are ventilator management (causing second-
ary lung injury) and extrapulmonary organ failures that may be 
influenced by patient management.7 The Scandinavian Society of 
Anaesthesiology and Intensive Care Medicine (SSAI) has issued 
evidence- based guidelines for the management of patients with 
ARDS,3,4 as well as fluid- and vasoactive drug management in the 
critically ill.37- 39 In webinars organised by Norwegian health au-
thorities early March, the importance of adherence to these and/
or similar guidelines5 was highlighted, with a strong emphasis on 
the principles of pressure- and volume limitation, fluid manage-
ment and avoidance of nephrotoxins.
A majority of Norwegian COVID- 19 patients were managed 
with mechanical ventilation and vasoactive support, and only 
F I G U R E  2   Survival estimates. Kaplan Meier estimates of survival of patients admitted to the ICU. Survival is reported for the overall 
group (blue) and by age (<65 years old [green] and ≥ 65 years old [red]). The analysis includes patients who survived the first day of intensive 
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14.7% needed RRT (Table 5). Need for vasoactive drugs in a ma-
jority of patients may presumably be explained by use of seda-
tive drugs (and a consequential drop in blood pressure) in most 
mechanically ventilated patients, rather than manifest circulatory 
failure. Renal replacement therapy was used in a minority of 
patients and in only 8.9% of total bed days. This contrasts with 
reports from other regions (UK: 26%,15 New York: 34%.)40 but res-
onates with data reviewed by Gabarre and co- workers.41 In pa-
tients with ARDS, the development of acute kidney injury (AKI) 
portends a severe prognosis.42 In New York, Chan and co- workers 
found AKI to be prevalent in ICU- patients with COVID- 19 and as-
sociated with a high risk of death (in- hospital mortality 52%).40 In 
a single- centre study in Modena, Italy, Alfano et al found AKI to be 
significant predictor of all- cause mortality.43 This is in agreement 
with an observed ICU- mortality rate of 53.1% in patients requiring 
RRT in our cohort.
4.1 | Strengths and limitations
This study is limited by the amount of data available for analysis. 
Firstly, a comparatively low mortality rate and small number of pa-
tients with COVID- 19 admitted to Norwegian ICUs preclude any 
detailed statistical analysis of risk- factors. Secondly, the NIPaR 
registry does not record details on patient management or mon-
itoring data and it only collects a small set of laboratory values. 
Specifically, very little data on ventilator settings are available for 
analyses. Moreover, because the timing of interventions is gener-
ally not available, modelling of the effects of interventions on mor-
tality becomes difficult due to the risk of immortal time bias. Finally, 
some data were provided at the discretion of clinicians involved: 
The cause(s) for admission to the ICU and classification of ARDS 
were provided without any qualifying criteria. As in other observa-
tional studies, we believe ARDS may have been under- recognised 
in patients with moderate severity of disease and short LOS.8
The strength of this report is that it is an analysis of a compre-
hensive and complete national dataset that includes all COVID- 19 
patients admitted to Norwegian ICUs and therefore describes a 
cross- section of both patients and their management in Norwegian 
ICUs during the first phase of the pandemic.
5  | CONCLUSIONS
In this national cohort of COVID- 19 patients admitted to Norwegian 
ICUs, acute hypoxaemic respiratory failure was the most common 
cause of admission to the ICU and severity of respiratory failure at 
admission was predictive of length of stay. Mortality was compara-
tively low and associated with age and chronic co- morbidities as well 
as severity of illness at admission.
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TA B L E  4   Outcomes (A) Mortality by premorbid patient 
characteristics– multivariable analysis. (B) Mortality by illness 
severity at admission– multivariable analysis
Risk factor HR 95% CI P
A
Age ≥ 65 years 3.01 1.52 5.95 <.01
Cardiovascular disease 1.07 0.56 2.07 .83
Diabetes 2.41 1.29 4.52 .01
Chronic lung disease 1.28 0.63 2.58 .49





1.00 - - - 
Mild 0.35 0.04 3.21 .35
Moderate 1.22 0.41 3.65 .72
Severe 2.47 0.79 7.77 .12
Kidney injury (s- urea)
S- UREA < 10 mmol/L 
(ref)
1.00 - - - 
S- UREA 
10- 29.9 mmol/L
3.89 2.02 7.50 <.01
S- UREA ≥ 30 mmol/L 5.60 1.20 26.23 .03
Systolic blood pressure
<70 mm Hg 2.42 0.87 6.73 .09
70- 99 mm Hg 1.00 0.49 2.06 .99
100- 199 mm Hg 1.00 - - - 
≥200 mm Hg 1.55 0.20 12.17 .68
The bold values show significant value.
Abbreviations: AHRF, acute hypoxaemic respiratory failure
TA B L E  5   Resource utilisation
N Mean (SD) Sum
% of 
LOS
ICU LOS (days) 217 17.4 (14.6) 3771.8 100.0
MV (days) 187 15.2 (12.8) 2840.9 75.3
NIV (days) 84 1.2 (1.4) 103.6 2.7
RRT (days) 32 10.5 (7.8) 335 8.9
ECMO (days) 2 17.5 (12.5) 35.0 0.9
NEMS 213 602.2 (517.5) 128 261 - 
Abbreviations: ICU LOS, intensive care length- of stay; MV, mechanical 
ventilation; NIV, non- invasive ventilation; RRT, renal replacement 
therapy; ECMO, extracorporeal ventilation; NEMS, Nine equivalents of 
nursing manpower score.
     |  627LAAKE Et AL
R E FE R E N C E S
 1. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory 
distress syndrome. JAMA. 2012;307(23):2526– 2533. https://doi.
org/10.1001/jama.2012.5669
 2. Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID- 
19- associated acute respiratory distress syndrome: a multicentre 
prospective observational study. Lancet Respir Med. 2020;8(12):1201– 
1208. https://doi.org/10.1016/s2213 - 2600(20)30370 - 2
 3. Claesson J, Freundlich M, Gunnarsson I, et al. Scandinavian clini-
cal practice guideline on mechanical ventilation in adults with 
the acute respiratory distress syndrome. Acta Anaesthesiol Scand. 
2015;59:286- 297.
 4. Claesson J, Freundlich M, Gunnarsson I, et al. Scandinavian clin-
ical practice guideline on fluid and drug therapy in adults with 
acute respiratory distress syndrome. Acta Anaesthesiol Scand. 
2016;60:697- 709.
 5. Fan E, Del Sorbo L, Goligher EC, et al. An official American Thoracic 
Society/European Society of intensive care medicine/Society of 
Critical Care Medicine Clinical Practice Guideline: mechanical ven-
tilation in adult patients with acute respiratory distress syndrome. 
Am J Respir Crit Care Med. 2017;195:1253- 1263.
 6. Murthy S, Gomersall CD, Fowler RA. Care for critically Ill pa-
tients with COVID- 19. JAMA. 2020;323:1499- 1500. https://doi.
org/10.1001/jama.2020.3633
 7. Laffey JG, Bellani G, Pham T, et al. Potentially modifiable factors 
contributing to outcome from acute respiratory distress syndrome: 
the LUNG SAFE study. Intensive Care Med. 2016;42:1865- 1876.
 8. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, 
and mortality for patients with acute respiratory distress syndrome 
in intensive care units in 50 countries. JAMA. 2016;315:788- 800.
 9. Laffey JG, Madotto F, Bellani G, et al. Geo- economic variations in 
epidemiology, patterns of care, and outcomes in patients with acute 
respiratory distress syndrome: insights from the LUNG SAFE pro-
spective cohort study. Lancet Respir Med. 2017;5:627- 638.
 10. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and 
outcomes of 1591 patients infected With SARS- CoV- 2 admitted to 
ICUs of the Lombardy REGION, Italy. JAMA. 2020;323(16):1574.
 11. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting char-
acteristics, comorbidities, and outcomes among 5700 patients 
hospitalized with COVID- 19 in the New York City area. JAMA. 
2020;323:2052- 2059. https://doi.org/10.1001/jama.2020.6775
 12. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically 
ill patients with SARS- CoV- 2 pneumonia in Wuhan, China: a single- 
centered, retrospective, observational study. Lancet Respir Med. 
2020;8:475- 481. https://doi.org/10.1016/S2213 - 2600(20)30079 - 5
 13. Grasselli G, Greco M, Zanella A, et al.Risk factors associated with 
mortality among patients with COVID- 19 in intensive care units in 
Lombardy, Italy. JAMA Intern Med. 2020;180:1345- 1355. https://
doi.org/10.1001/jamai ntern med.2020.3539
 14. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid- 19 in criti-
cally Ill patients in the Seattle region - case series. N Engl J Med. 
2020;382:2012- 2022.
 15. ICNARC report on COVID- 19 in critical care. 2020. https://www.
icnarc.org/Our- Audit/ Audit s/Cmp/Reports
 16. Argenziano MG, Bruce SL, Slater CL, et al. in New York: retro-
spective case series. BMJ. 2019;2020(369):m1996. https://doi.
org/10.1136/bmj.m1996
 17. Mitra AR, Fergusson NA, Lloyd- Smith E, et al. Baseline charac-
teristics and outcomes of patients with COVID- 19 admitted to 
intensive care units in Vancouver, Canada: a case series. CMAJ. 
2020;192:E694- E701. https://doi.org/10.1503/cmaj.200794
 18. Vanderburg S, Alipanah N, Crowder R, et al. Management and 
outcomes of critically- Ill patients with COVID- 19 Pneumonia at 
a Safety- net Hospital in San Francisco, a region with early pub-
lic health interventions: a case series. MedRxiv. 2020. https://doi.
org/10.1101/2020.05.27.20114090
 19. Ferguson J, Rosser JI, Quintero O, et al. Characteristics and out-
comes of coronavirus disease patients under Nonsurge conditions, 
F I G U R E  3   Length of stay. Length of stay (LOS) in the ICU by severity of respiratory failure at ICU admission. The boxplots illustrate LOS 
(days) for patients not requiring MV on the first day of admission, and MV patients with mild (pf- ratio > 26.6 kPa), moderate (pf- ratio > 13.3 
and ≤ 26.6 kPa) or severe (pf- ratio ≤ 13.3 kPa) AHRF. LOS was significantly longer in patients requiring MV compared to patients who did 
not require MV and in patients with moderate or severe AHRF compared to those with mild AHRF. LOS was analysed with multiple linear 


















* p < 0.01
628  |     LAAKE Et AL
Northern California, USA, march- april 2020. Emerging Infect Dis. 
2020;26:343- 1685.
 20. Auld SC, Caridi- Scheible M, Blum JM, et al. ICU and ventilator 
mortality among critically Ill adults with coronavirus disease 2019. 
Crit Care Med. 2020;48:e799- e804. https://doi.org/10.1097/
CCM.00000 00000 004457
 21. Norwegian Institute of Public Health. Daily report and statistics 
about coronavirus and COVID- 19. 2020 https://www.fhi.no/en/
id/infec tious - disea ses/coron aviru s/daily - repor ts/daily - repor ts- 
COVID 19/
 22. Ministry of Health and Care Services. Timeline: News from 
Norwegian Ministries about the Coronavirus disease COVID- 19. 
2020. https://www.regje ringen.no/en/topic s/koron aviru s- covid - 19/
timel ine- for- news- from- norwe gian- minis tries - about - the- coron aviru 
s- disea se- covid - 19/id269 2402/
 23. Norwegian intensive care registry. Mal for data og kodebok. 2020. https://
helse - bergen.no/norsk - inten sivre giste r- nir/mal- for- data- og- kodebok
 24. Norwegian intensive care registry. Yearly Report 2020. https://
helse - bergen.no/norsk - inten sivre giste r- nir/arsra pportar
 25. Norwegian intensive care registry. Informasjon til forskere. 2020. 
https://helse - bergen.no/norsk - pande mireg ister/ infor masjo 
n- til- forskere
 26. Turnbull AE, Sepulveda KA, Dinglas VD, Chessare CM, Bingham 
CO, Needham DM. Core domains for clinical research in acute re-
spiratory failure survivors: an international modified delphi consen-
sus study. Crit Care Med. 2017;45:1001- 1010.
 27. Needham DM, Sepulveda KA, Dinglas VD, et al. Core outcome mea-
sures for clinical research in acute respiratory failure survivors: an 
international modified Delphi consensus study. Am J Respir Crit Care 
Med. 2017;196:1122- 1130.
 28. Needham DM, Davidson J, Cohen H, et al. Improving long- term 
outcomes after discharge from intensive care unit: report from a 
stakeholders' conference. Crit Care Med. 2012;40:502- 509.
 29. Brown SM, Wilson EL, Presson AP, et al. Understanding patient 
outcomes after acute respiratory distress syndrome: identify-
ing subtypes of physical, cognitive and mental health outcomes. 
Thorax. 2017;72:1094- 1103. https://doi.org/10.1136/thora xjnl- 
2017- 21033 7:thora xjnl- 2017- 210337
 30. Norwegian Institutre of Public Health. Coronavirus disease - advice 
and information. 2020. https://www.fhi.no/en/id/infec tious - disea 
ses/coron aviru s/
 31. Quah P, Li A, Phua J. Mortality rates of patients with COVID- 19 in 
the intensive care unit: a systematic review of the emerging litera-
ture. Crit Care. 2020;24:285- 294.
 32. Richards- Belle A, Orzechowska I, Gould DW, et al. COVID- 19 in 
critical care: epidemiology of the first epidemic wave across 
England, Wales and Northern Ireland. Intensive Care Med. 
2020;46:833- 913.
 33. Haase N, Plovsing R, Christensen S, et al. Characteristics, inter-
ventions, and longer term outcomes of COVID- 19 ICU patients 
in Denmark- A nationwide, observational study. Acta Anaesthesiol 
Scand. 2021;65:68- 75. https://doi.org/10.1111/aas.13701
 34. Kristinsson B, Kristinsdottir LB, Blondal AT, et al. Nationwide 
incidence and outcomes of patients with coronavirus dis-
ease 2019 requiring intensive care in Iceland. Crit Care Med. 
2020;48:e1102- e1105.
 35. Chew MS, Blixt P, Ahman R, et al. Characteristics and outcomes 
of patients admitted to Swedish intensive care units for COVID- 19 
during the first 60 days of the 2020 pandemic: a registry- based, 
multicenter, observational study. medRxiv. 2020. https://doi.org/10.
1101/2020.08.06.20169599.
 36. Rockwood K, Song X, MacKnight C, et al. A global clinical measure 
of fitness and frailty in elderly people. CMAJ. 2005;173:489- 495.
 37. Perner A, Junttila E, Haney M, et al. Scandinavian clinical prac-
tice guideline on choice of fluid in resuscitation of critically ill 
patients with acute circulatory failure. Acta Anaesthesiol Scand. 
2015;59:274- 285.
 38. Møller MH, Claudius C, Junttila E, et al. Scandinavian SSAI clini-
cal practice guideline on choice of first- line vasopressor for pa-
tients with acute circulatory failure. Acta Anaesthesiol Scand. 
2016;60:1347- 1366.
 39. Møller MH, Granholm A, Junttila E, et al. Scandinavian SSAI 
clinical practice guideline on choice of inotropic agent for pa-
tients with acute circulatory failure. Acta Anaesthesiol Scand. 
2018;62:420- 450.
 40. Chan L, Chaudhary K, Saha A, et al. Acute kidney injury in hos-
pitalized patients with COVID- 19. medRxiv. 2020. https://doi.
org/10.1101/2020.05.04.20090944
 41. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. 
Acute kidney injury in critically ill patients with COVID- 19. Intensive 
Care Med. 2020;96:1083- 1110.
 42. McNicholas BA, Rezoagli E, Pham T, et al. Impact of early acute kid-
ney injury on management and outcome in patients with acute re-
spiratory distress syndrome: A secondary analysis of a multicenter 
observational study. Crit Care Med. 2019;47:1216- 1225.
 43. Alfano G, Ferrari A, Fontana F, et al. Incidence, risk factors and mor-
tality outcome in patients with acute kidney injury in COVID- 19: 
a single- center observational study. medRxiv. 2020. https://doi.
org/10.1101/2020.06.24.20138230
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Laake JH, Buanes EA, Småstuen MC, 
et al. Characteristics, management and survival of ICU 
patients with coronavirus disease- 19 in Norway, March- June 
2020. A prospective observational study. Acta Anaesthesiol 
Scand. 2021;65:618– 628. https://doi.org/10.1111/aas.13785
